Boehringer targets Tovok in Phase III first-line lung cancer trial
This article was originally published in Scrip
Boehringer Ingelheim will commence a Phase III study investigating its oral dual EGFR and HER2 inhibitor, BIBW 2992 (planned brand name Tovok), as first-line treatment for non-small cell lung cancer (NSCLC) patients with EGFR mutations, after observing high response rates in a Phase II trial in this patient population.
You may also be interested in...
The development of drugs to prevent cancer has lagged far behind the development of drugs, such as the statins, to prevent cardiovascular disease. But consideration of new, "personalised" clinical trial designs and an improved understanding of the biology of precancers, as well as new agents which target their molecular abnormalities, may make the field a more promising investment, says Malini Guha.
Janssen-Cilag's (Johnson & Johnson) injectable drug Xeplion (paliperidone palmitate) has been recommended for European approval by the CHMP for the treatment of schizophrenia.
The CHMP has recommended for European approval Pfizer's Xiapex (collagenase clostridium histolyticum) for the treatment of Dupuytren’s contracture, a potentially debilitating hand condition.